A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 522 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast... April 12, 2021 Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... March 19, 2020 Pausing Long-Term Breast Cancer Therapy to Become Pregnant Appears to Be... January 20, 2023 Load more HOT NEWS Singer Rebecca Crews, Wife Of Terry Crews, Diagnosed With Breast Cancer... Bean there done that: Can swapping to pulses be the new... Celebrating 20 Years of Cancer.Net: How We’ve Worked to Empower People... Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of...
